|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Targeting the PI3K-AKT-mTOR signaling network in cancer显示文摘The phosphoinositide 3-kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR) pathway is a frequently hyperactivated pathway in cancer and is important for tumor cell growth and survival. The development of targeted therapies against mTOR, a vital substrate along this pathway, led to the approval of allosteric inhibitors, including everolimus and temsirolimus, for the treatment of breast, renal, and pancreatic cancers. However, the suboptimal duration of response in unselected patients remains an unresolved issue. Numerous novel therapies against critical nodes of this pathway are therefore being actively investigated in the clinic in multiple tumour types. In this review, we focus on the progress of these agents in clinical development along with their biological rationale, the need of predictive biomarkers and various combination strategies, which will be useful in counteracting the mechanisms of resistance to this class of drugs. | Khurum H. Khan Timothy A. Yap Li Yan David Cunningham | 2013 | Chinese Journal of Cancer2013，32，5： | 25 |
| 2 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial显示文摘 | Tom Waddell Ian Chau David Cunningham David Gonzalez Alicia Frances Clare Okines Andrew Wotherspoon Claire Saffery Gary Middleton Jonathan Wadsley David Ferry Wasat Mansoor Tom Crosby Fareeda Coxon David Smith Justin Waters Timothy Iveson Stephen Falk Sar | 2013 | Lancet Oncology2013，，6： | 10 |
| 3 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial显示文摘 | Hansjochen Wilke Kei Muro Eric Van Cutsem Sang-Cheul Oh Gy?rgy Bodoky Yasuhiro Shimada Shuichi Hironaka Naotoshi Sugimoto Oleg Lipatov Tae-You Kim David Cunningham Philippe Rougier Yoshito Komatsu Jaffer Ajani Michael Emig Roberto Carlesi David Ferry Kuma | 2014 | Lancet Oncology2014，，11： | 4 |
| 4 | Colorectal cancer显示文摘 | David Cunningham Wendy Atkin Heinz-Josef Lenz Henry T Lynch Bruce Minsky Bernard Nordlinger Naureen Starling | 2010 | The Lancet2010，，9719： | 3 |
| 5 | Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial显示文摘 | Aimery de Gramont Eric Van Cutsem Hans-Joachim Schmoll Josep Tabernero Stephen Clarke Malcolm J Moore David Cunningham Thomas H Cartwright J Randolph Hecht Fernando Rivera Seock-Ah Im Gy?rgy Bodoky Ramon Salazar Frédérique Maindrault-Goebel Einat Shacham- | 2012 | Lancet Oncology2012，，12： | 3 |
| 6 | Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer显示文摘 | Uzma Asghar Eliza Hawkes David Cunningham | 2010 | Clinical Colorectal Cancer2010，，5： | 2 |
| 7 | Colorectal cancer显示文摘 | David Cunningham Wendy Atkin Heinz-Josef Lenz Henry T Lynch Bruce Minsky Bernard Nordlinger Naureen Starling | 2010 | The Lancet2010，，9719： | 2 |
| 8 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer显示文摘 | Corcoran Ryan B. Atreya Chloe E. Falchook Gerald S. Kwak Eunice L. Ryan David P. Bendell Johanna C. Hamid Omid Messersmith Wells A. Daud Adil Kurzrock Razelle Pierobon Mariaelena Sun Peng Cunningham Elizabeth Little Shonda Orford Keith Motwani Monica Bai | 2015 | Journal of Clinical Oncology2015，，34： | 2 |
| 9 | Functional Defects in the Fanconi Anemia Pathway in Pancreatic Cancer Cells显示文摘 | Michiel S. Van der Heijden Jonathan R. Brody Eike Gallmeier Steven C. Cunningham David A. Dezentje Dong Shen Ralph H. Hruban Scott E. Kern | 2004 | The American Journal of Pathology2004，，2： | 2 |
| 10 | The role of probiotics in aquaculture显示文摘 | José Luis Balcázar Ignacio de Blas Imanol Ruiz-Zarzuela David Cunningham Daniel Vendrell José Luis Múzquiz | 2006 | Veterinary Microbiology2006，，3： | 2 |
| 11 | Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study显示文摘 | Julia Granerod Helen E Ambrose Nicholas WS Davies Jonathan P Clewley Amanda L Walsh Dilys Morgan Richard Cunningham Mark Zuckerman Ken J Mutton Tom Solomon Katherine N Ward Michael PT Lunn Sarosh R Irani Angela Vincent David WG Brown Natasha S Crowcroft | 2010 | The Lancet Infectious Diseases2010，，12： | 2 |
| 12 | Colorectal cancer显示文摘 | David Cunningham Wendy Atkin Heinz-Josef Lenz Henry T Lynch Bruce Minsky Bernard Nordlinger Naureen Starling | 2010 | The Lancet . 2010 (9719)2010，，9719： | 2 |
| 13 | Assessment of herbal medicinal products: Challenges, and opportunities to increase the knowledge base for safety assessment显示文摘 | Scott A. Jordan David G. Cunningham Robin J. Marles | 2009 | Toxicology and Applied Pharmacology2009，，2： | 2 |
| 14 | Meta- Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer显示文摘 | Asma Sultana Catrin Tudur Smith David Cunningham | 2007 | J Clin Oncol2007，25，18： | 1 |
| 15 | Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease显示文摘 | David Cunningham David Cunningham Alicia Okines | 2011 | Gastrointestinal Cancer: Targets and Therapy (default)2011，，： | 1 |
| 16 | Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles显示文摘 | David Cunningham Eliza A Hawkes Andrew Jack Wendi Qian Paul Smith Paul Mouncey Christopher Pocock Kirit M Ardeshna John A Radford Andrew McMillan John Davies Deborah Turner Anton Kruger Peter Johnson Joanna Gambell David Linch | 2013 | The Lancet2013，，9880： | 1 |
| 17 | Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer显示文摘 | Alicia F.C. Okines David Cunningham | 2012 | Therapeutic Advances in Gastroenterology2012，，5： | 1 |
| 18 | Chemotherapy for Operable Gastric Cancer: Current Perspectives显示文摘 | Vikram K. Jain David Cunningham Sheela Rao | 2011 | Indian Journal of Surgical Oncology2011，，4： | 1 |
| 19 | Early hepatocellular carcinoma:transplantation versus resection:the case for liver resection显示文摘 | Merchant N David CS Cunningham SC | | 0，，： | 1 |
| 20 | Comparison of the effects of di-(2-ethylhexyl)adipate on hepatic peroxisome proliferation and cell replication in the rat and mouse 1 Presented in part at the Annual Meeting of the Society of Toxicology, Dallas, Texas, March 13–17, 1994. 1显示文摘 | Brian G Lake Roger J Price Morag E Cunninghame David G Walters | 1997 | Toxicology1997，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员